How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC

from TheBrief.Health · host TheBrief.Health

A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.

Episode metadata supplied by the publisher feed · Published Jun 22, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC

0:00 1:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on June 22, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!